Next-generation anti-VEGF agents for diabetic macular oedema
© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists..
The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
---|---|
Enthalten in: |
Eye (London, England) - 36(2022), 2 vom: 09. Feb., Seite 273-277 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Iglicki, Matias [VerfasserIn] |
---|
Links: |
---|
Themen: |
2S9ZZM9Q9V |
---|
Anmerkungen: |
Date Completed 15.04.2022 Date Revised 02.02.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41433-021-01722-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM329177028 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM329177028 | ||
003 | DE-627 | ||
005 | 20231225204541.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41433-021-01722-8 |2 doi | |
028 | 5 | 2 | |a pubmed24n1097.xml |
035 | |a (DE-627)NLM329177028 | ||
035 | |a (NLM)34373607 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Iglicki, Matias |e verfasserin |4 aut | |
245 | 1 | 0 | |a Next-generation anti-VEGF agents for diabetic macular oedema |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.04.2022 | ||
500 | |a Date Revised 02.02.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists. | ||
520 | |a The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
650 | 7 | |a Bevacizumab |2 NLM | |
650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
700 | 1 | |a González, David Pérez |e verfasserin |4 aut | |
700 | 1 | |a Loewenstein, Anat |e verfasserin |4 aut | |
700 | 1 | |a Zur, Dinah |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Eye (London, England) |d 1995 |g 36(2022), 2 vom: 09. Feb., Seite 273-277 |w (DE-627)NLM012628646 |x 1476-5454 |7 nnns |
773 | 1 | 8 | |g volume:36 |g year:2022 |g number:2 |g day:09 |g month:02 |g pages:273-277 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41433-021-01722-8 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 36 |j 2022 |e 2 |b 09 |c 02 |h 273-277 |